A Phase II Study of Plitidepsin in Patients with Angioimmunoblastic T-cell Lymphoma. Estudio de fase II de plitidepsin en pacientes con linfoma angioinmunoblástico de células T To evaluate the efficacy of plitidepsin on the basis of overall response rate (ORR) in patients with relapsing/refractory angioimmunoblastic T-cell lymphoma (AITL). Evaluar la eficacia de plitid...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma To compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (M...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) To evaluate the efficacy of trabectedin vs. standard DXCT as first-line treatment of patients with advanced TRS, by comparing PFS in each treatment arm.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram The objective of this study is to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in subjects with advanced solid tumor malignancies w...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacité et Tolérance de la Plitidepsine chez les patients souffrant d’un liposarcome dédifférencié (DLPS) avancé, non opérable ou métastatique, en rechute/réfractaire : Une étude exploratoire multicentrique de phase II To evaluate the antitumor activity of plitidepsin in terms of progression-free survival rate at three months (PFS3).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide . Ensayo Fase II de Plitidepsin (Aplidin®) en Combinación con Bortezomib y Dexametasona en Pacientes con Mieloma Múltiple Doble Refractario a bortezomib y lenalidomida To evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with multiple myeloma (MM) double refractory to bortezomib and lenalidomide in terms of overall res...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma - To determine the pathological complete response (pCR) rate with trabectedin in patients with locally advanced (Stage III) myxoid / round cell liposarcoma (MRCL).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoral basada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP) Avanzado con Sobreexpresión de XPG y/o ERCC1, y Subexpresión de BRCA1 Evaluar la eficacia de trabectedina en pacientes con CNMP y que presenten sobreexpresión de ERCC1 y/o XPG, y baja expresión de BRCA1, después de fallo al tratamiento estándar basado en platino. Para e...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin® as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urothelium, relapsing or progressing after first line chemotherapy To assess the anti-tumor activity of Aplidin® administered as a 3 h iv infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urothelium, relapsing or progr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers Primary Objective: to determine the objective response rate by RECIST (Complete and Partial Response [CR + PR]) with trabectedin in patients with the following metastatic breast cancer subtypes: Group...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune